Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Multi-parametric flow cytometry in the evaluation of plasma cell proliferative disorders- Current paradigms for clinical practice
Plasma cell proliferative disorders (PCPDs) comprise a spectrum of disorders arising from clonal plasma cells (PCs) with variable disease phenotype ranging from benign premalignant state of Monoclonal Gammopathy of Undetermined Significance (MGUS) to indolent state of Smoldering Multiple Myeloma (SMM) to overt malignant phenotype of Multiple Myeloma (MM), some of which may progress to a clinically aggressive leukemic state of Plasma Cell leukemia (PCL). In MGUS, SMM and MM, the primary disease is intramedullary whereas PCL has a hematogenous spread. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Ritu Gupta, Dragan Jevremovic, Smith J. Mathew, Shaji Kumar Tags: Review Article Source Type: research

SOHO State of the Art Update and Next Questions | Novel Therapies for Polycythemia Vera
In the recent years, landmark advancements in the treatment of polycythemia vera (PV) have been achieved. We witnessed the regulatory approval of ropeginterferon and the advanced clinical development of other novel agents that may affect the underlying pathophysiological mechanisms of the disease. Agents with the potential of disease modification may soon overtake preceding treatment options that were based on the patient's age and history of thrombosis. Recent studies using ropeginterferon in low-risk PV patients earlier in the disease course challenge the current treatment paradigm and shift the focus on modifying the co...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Lucia Masarova, Helen T. Chifotides Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2023 Category: Hematology Source Type: research

The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults representing approximately 30% of cases1 with an estimated annual incidence of 6-7 cases per 100,000 person-year in western countries and higher rates in males and older individuals2. The median age at diagnosis is in the mid-60s and 30% of patients are over 75 years of age1. The International Prognostic Index (IPI) is the primary clinical tool to predict outcomes estimating a 4-year PFS and a 4-year OS for patients with DLBCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2023 Category: Hematology Authors: Gabriel Roman Souza, Zohra Nooruddin, Sophia Lee, Lauren Boyle, Kana Tai Lucero, Snegha Ananth, Kathleen Franklin, Michael Mader, Esteban Toro Velez, Amna Naqvi, Supreet Kaur Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia
Philadelphia-chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) has historically been associated with poor outcomes in older patients due to adverse disease biology, as well as inferior tolerance of conventional chemotherapy. Fortunately, novel therapies, including inotuzumab ozogamicin, blinatumomab, and venetoclax, are now being incorporated into first-line therapy to improve efficacy and decrease toxicity of initial therapy. Inotuzumab ozogamicin, alone or in combination with low intensity chemotherapy, appears to be best suited for the induction phase of treatment due to efficacy in the setting of high tum...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2023 Category: Hematology Authors: Shai Shimony, Marlise R. Luskin Tags: Review Article Source Type: research

Approach to Older Adults with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia
Philadelphia-chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) has historically been associated with poor outcomes in older patients due to adverse disease biology, as well as inferior tolerance of conventional chemotherapy. Fortunately, novel therapies, including inotuzumab ozogamicin, blinatumomab, and venetoclax, are now being incorporated into first-line therapy to improve efficacy and decrease toxicity of initial therapy. Inotuzumab ozogamicin, alone or in combination with low intensity chemotherapy, appears to be best suited for the induction phase of treatment due to efficacy in the setting of high tum...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2023 Category: Hematology Authors: Shai Shimony, Marlise R. Luskin Tags: Review Article Source Type: research

Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes from a Single-Center Study
Detection of measurable residual disease (MRD) in adults with acute lymphoblastic leukemia (ALL) is a vital biomarker in risk prediction and treatment selection. Next-generation sequencing (NGS) offers greater sensitivity relative to multiparametric flow cytometry (MFC) and may be a better predictive tool for identifying ALL patients at risk of relapse. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 18, 2023 Category: Hematology Authors: Karam Ashouri, Vinay Nittur, Anush A. Ginosyan, Jennifer Hwang, Blake Adnani, Denaly Chen, Lakshmi Sav itala-Damerla, Kimberly Schiff, Preet Chaudhary, Alexandra E. Kovach, Abdullah Ladha, Imran Siddiqi, Amir Ali, Karrune Woan, Eric Tam, George Yaghmour Tags: Original Study Source Type: research

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase 2 MajesTEC-1 Study
Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. Therefore, consideration of the impact of treatment on HRQoL in addition to clinical outcomes is vital. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 13, 2023 Category: Hematology Authors: Thomas G. Martin, Philippe Moreau, Saad Z. Usmani, Alfred Garfall, Mar ía-Victoria Mateos, Jesús F. San-Miguel, Albert Oriol, Ajay K. Nooka, Laura Rosinol, Ajai Chari, Lionel Karlin, Amrita Krishnan, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquín Source Type: research

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Multiple myeloma (MM) remains incurable and follows a relapsing-remitting cycle.1,2 Despite significant advances in therapy, particularly the introduction of immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, patients with relapsed/refractory MM (RRMM) typically have poorer outcomes following each subsequent treatment.1-3 In newly diagnosed MM, lenalidomide now forms part of the standard of care as a component of triplet regimens or as maintenance therapy.3,4 This has resulted in a population of patients with MM who are refractory to lenalidomide early in their treatment due to remaining on lenalido...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 7, 2023 Category: Hematology Authors: Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, Meral Beksac, Thierry Facon, Sujith Dhanasiri, Shien Guo, Yutian Mu, Kevin Hong, Christian Gentili, Monica Galli, Munci Yagci, Alessandra Larocca, Paul Richardson, Katja Weisel Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2023 Category: Hematology Source Type: research

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
High-dose methotrexate (HDMTX)-based regimens are the treatment of choice in primary central nervous system lymphoma (PCNSL). Folinic acid (FA) rescue is used to mitigate the toxic effects of MTX on normal cells. However, the optimal dosing of FA in PCNSL remains uncertain. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 31, 2023 Category: Hematology Authors: Arnon Haran, Noa Gross Even-Zohar, Michal Haran, Eyal Lebel, Shlomzion Aumann, Adir Shaulov, Moshe Gatt, Boaz Nachmias Tags: Original Study Source Type: research

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)
We sought to understand the clinical effectiveness associated with use of hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DEC) for patients with refractory anemia with excess blasts (RAEB; an established proxy for higher-risk myelodysplastic syndromes/neoplasms) in contemporary and representative real-world settings. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 28, 2023 Category: Hematology Authors: Amer M. Zeidan, Elizabeth S. Mearns, Carmen D. Ng, Anuj Shah, Neil Lamarre, Archibong Yellow-Duke, Neda Alrawashdh, Baiyu Yang, Wei-Han Cheng, Cat N. Bui, Anders Svensson Tags: Original Study Source Type: research

Long-term follow-up in patients with chronic myeloid leukemia treated with ponatinib in a real-world cohort. Safety and efficacy analysis
Specific tyrosine kinase inhibitors (TKI) have strongly modified the treatment approach for patients with chronic myeloid leukemia (CML).1 TKIs and allogeneic stem cell transplantation in CML patients have contributed to a life expectancy that largely approaches that of the general adult population.2 However, several challenges remain to be addressed in CML management, including TKI resistance, which may occur either de novo or during treatment, as a result of BCR::ABL1-dependent or -independent mechanisms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 25, 2023 Category: Hematology Authors: Mar ía José Mela Osorio, Beatriz Moiraghi, María Victoria Osycka, Miguel A. Pavlovsky, Ana Inés Varela, Georgina Emilia Bendek Del Prete, María Fernanda Tosin, Mariel Ana Pérez, María Elisa Riva, Roxana Ramírez Berrios, Isolda Fernández I, Federi Tags: Original Study Source Type: research